TW202325738A - 抗ctla-4抗體給藥方案 - Google Patents

抗ctla-4抗體給藥方案 Download PDF

Info

Publication number
TW202325738A
TW202325738A TW111141150A TW111141150A TW202325738A TW 202325738 A TW202325738 A TW 202325738A TW 111141150 A TW111141150 A TW 111141150A TW 111141150 A TW111141150 A TW 111141150A TW 202325738 A TW202325738 A TW 202325738A
Authority
TW
Taiwan
Prior art keywords
ctla
cancer
antibody
seq
dose
Prior art date
Application number
TW111141150A
Other languages
English (en)
Chinese (zh)
Inventor
陽 劉
盼 鄭
馬汀 戴芬波特
Original Assignee
美商昂科Ｃ４公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商昂科Ｃ４公司 filed Critical 美商昂科Ｃ４公司
Publication of TW202325738A publication Critical patent/TW202325738A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111141150A 2021-10-29 2022-10-28 抗ctla-4抗體給藥方案 TW202325738A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
US63/273,660 2021-10-29

Publications (1)

Publication Number Publication Date
TW202325738A true TW202325738A (zh) 2023-07-01

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111141150A TW202325738A (zh) 2021-10-29 2022-10-28 抗ctla-4抗體給藥方案

Country Status (9)

Country Link
EP (1) EP4422685A4 (enExample)
JP (1) JP2024540152A (enExample)
KR (1) KR20240099187A (enExample)
CN (1) CN118176021A (enExample)
AU (1) AU2022377644A1 (enExample)
CA (1) CA3234351A1 (enExample)
MX (1) MX2024004429A (enExample)
TW (1) TW202325738A (enExample)
WO (1) WO2023077069A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121358769A (zh) * 2023-05-17 2026-01-16 昂科医药 Ph敏感性抗ctla-4抗体及其用途
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Also Published As

Publication number Publication date
MX2024004429A (es) 2024-05-06
EP4422685A1 (en) 2024-09-04
CA3234351A1 (en) 2023-05-04
EP4422685A4 (en) 2025-12-03
AU2022377644A1 (en) 2024-05-16
KR20240099187A (ko) 2024-06-28
CN118176021A (zh) 2024-06-11
JP2024540152A (ja) 2024-10-31
WO2023077069A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7519477B2 (ja) 非小細胞肺がんを治療するための抗ｂ７－ｈ１および抗ｃｔｌａ－４抗体
KR102661249B1 (ko) 종양 치료용 항-ｂ7-ｈ1 항체
CN110882385A (zh) 抗pd-1抗体在治疗肿瘤中的用途
TW202325738A (zh) 抗ctla-4抗體給藥方案
TW202342096A (zh) 靶向dll3的癌症治療
JP2021501150A (ja) 肝臓がんを治療するための組成物及び方法
US20260092112A1 (en) Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
CN117479955A (zh) 允许免疫细胞浸润到肿瘤中的方法
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
JP2024534080A (ja) 誘導性ｉｌ－２及びｐｄ－１／ｐｄ－ｌ１の併用療法
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
JP2024513247A (ja) 抗ｐｄ－１抗体の皮下投与によるがんの治療方法
JP2025504278A (ja) 抗ｐｄ１抗体の皮下投与により癌を治療するための組成物及び方法
HK40106641A (zh) 抗ctla-4抗体给药方案
WO2019070497A1 (en) POLY THERAPY AGAINST CANCER
WO2025185682A1 (zh) 含有抗egfr抗体或其片段的联合用药物
TW202612729A (zh) 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體以及抗ｐｄ－１抗體之組合療法
TW202517679A (zh) 以抗ｉｌｔ２抗體治療癌症
JP2025524957A (ja) 抗ＧＡＲＰ－ＴＧＦ－β１／ＰＤ－１併用療法
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
TW202604568A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
HK1224560B (zh) 用於治疗肿瘤的抗b7-h1抗体